Immutep (IMMP) Income from Continuing Operations (2012 - 2024)
Immutep's (IMMP) quarterly Income from Continuing Operations came in at 2641465.42 in Q4 2024, down 113.59% YoY from 19434895.67 in Q1 2024, and down 4.37% on a QoQ basis from 2530854.37 in Q2 2024.
Immutep (IMMP) Income from Continuing Operations (2012 - 2024) Analysis & Trends
Immutep (IMMP) has 10 years of Income from Continuing Operations data on file, last reported at 2641465.42 in Q4 2024.
- Quarterly Income from Continuing Operations fell 113.59% year-over-year to 2641465.42 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 6943031.05 (down 142.41% YoY) and the FY2025 annual result came in at 39344479.08, down 35.26% from the prior year.
- Income from Continuing Operations slipped to 2641465.42 in Q4 2024, from 2530854.37 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 422669.57 in Q4 2021 to a low of 2641465.42 in Q4 2024.
- A 4-year average of 1473140.12 and a median of 1236691.17 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations retreated 26.34% — and 2023, when it tumbled 131.58%.
- Tracing IMMP's Income from Continuing Operations over 4 years: stood at 422669.57 in 2021, then fell by 26.34% to 534020.09 in 2022, then slumped by 131.58% to 1236691.17 in 2023, then slumped by 113.59% to 2641465.42 in 2024.
- The last three Income from Continuing Operations figures came in at 2641465.42 (Q4 2024), 2530854.37 (Q2 2024), and 1236691.17 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.64 Mn |
| Jun 30, 2024 | -2.53 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Dec 31, 2022 | -534,020.09 |
| Dec 31, 2021 | -422,669.57 |
| Dec 31, 2019 | -670,750.76 |
| Jun 30, 2019 | -1.30 Mn |
| Dec 31, 2018 | -944,731.60 |
| Jun 30, 2017 | -1.99 Mn |
| Mar 31, 2017 | -1.80 Mn |
| Dec 31, 2016 | -461,772.75 |
| Jun 30, 2016 | -1.77 Mn |
| Mar 31, 2016 | -1.99 Mn |
| Jun 30, 2015 | -4.98 Bn |
| Dec 31, 2012 | 69,562.20 |